| City of Hope |
|
City of Hope |
Cancer - Brain |
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Brain |
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Leukemia |
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
Recruiting |
|
| City of Hope |
|
Adaptimmune |
Cancer - Lung |
A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
|
| City of Hope |
|
Adaptimmune |
Cancer - Lung |
Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC |
Recruiting |
|
| City of Hope |
|
Adaptimmune |
Cancer - Ovarian |
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. |
Recruiting |
|
| City of Hope |
|
Sangamo Therapeutics |
Hemophilia B |
Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B |
Recruiting |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) |
Recruiting |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1) |
Recruiting |
|
| City of Hope |
|
Tessa Therapeutics |
Cancer - Nasopharyngeal Carcinoma |
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea |
Recruiting |
|
| UCLA |
|
UCLA |
Sickle Cell Disease |
Stem Cell Gene Therapy for Sickle Cell Disease |
Recruiting |
|
| UCSD |
|
Neuralstem |
Spinal Cord Injury |
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI |
Recruiting |
|
| City of Hope |
|
Sangamo Therapeutics |
Hemophilia A |
Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A |
Recruiting |
|
| City of Hope |
|
Adaptimmune |
Cancer - Myeloma |
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma |
Recruiting |
|
| City of Hope |
|
Celgene |
Cancer - Lymphoma |
An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) |
Recruiting |
|
| City of Hope |
|
City of Hope |
Sickle Cell Disease |
A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant |
Recruiting |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) |
Recruiting |
|
| City of Hope |
|
City of Hope |
Neurodegenerative Disorder |
Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies |
Recruiting |
|
| UCSF |
|
UCSF |
Blood Disorder - Alpha Thalassemia Major |
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) |
Recruiting |
|
| UC Davis |
|
UC Davis |
Eye - Retinopathy |
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy |
Recruiting |
|
| UC Davis |
|
UC Davis |
Cancer - Tongue Dysphagia |
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia |
Recruiting |
|
| UC Davis |
|
UC Davis |
Cancer - Lymphoma (HIV-Related) |
Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
Recruiting |
|
| City of Hope |
|
Angiocrine Bioscience |
Cancer - Leukemia |
A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation |
Recruiting |
|
| City of Hope |
Elizabeth Budde, MD
626-218-2405 |
Kite Pharma |
Cancer - Lymphoma |
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Brain |
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma |
Recruiting |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Myeloma |
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE) |
Recruiting |
|
| City of Hope |
|
City of Hope |
Sickle Cell Disease |
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Brain |
HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases |
Recruiting |
|
| City of Hope |
|
Children’s Hospital Los Angeles |
Infection After Stem Cell Transplant |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution |
Recruiting |
|
| UCSF |
|
Stanford University |
Severe Combined Innunodeficiency (SCID) |
AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients |
Recruiting |
|
| UC Davis |
|
Pluristem Ltd. |
Muscle Injury - hip fracture |
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty |
Recruiting |
|
| UC Davis |
|
Orca Biosystems, Inc. |
Hematologic Malignancies |
A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood, With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
Recruiting |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) |
Recruiting |
|
| City of Hope |
|
Precision BioSciences, Inc. |
Cancer - Lymphoma |
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL |
Recruiting |
|
| City of Hope |
|
Novartis Pharmaceuticals |
Cancer - Lymphona |
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) |
Recruiting |
|
| City of Hope |
|
Janssen Research & Development, LLC. |
Cancer - Myeloma |
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Prostate |
PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
Recruiting |
|
| City of Hope |
|
Torque Therapeutics, Inc. |
Cancer - Lymphoma |
TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas |
Recruiting |
|
| UCSF |
|
UCSF |
Graft versus Host Disease (GvHD) |
An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients |
Recruiting |
|
| UC Davis |
|
UC Davis/CIRM |
Spina bifida |
Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele |
Recruiting |
|
| UC Davis |
|
Orca Biosystems Inc. |
Hematologic Malignancies |
A Study of Engineered Donor Grafts (TregGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
Recruiting |
|
| UCSD |
|
UCSD & CIRM |
Cystinosis |
Stem cell gene therapy for cystinosis |
Recruiting |
|
| UC Davis |
|
Capricor Therapeutics |
Duchenne Muscular Dystrophy |
Open-Lael Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial (HOPE-2-OLE) |
Recruiting |
|
| UC Davis |
|
Cabaletta |
Pemphigus Vulgaris |
Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris |
Recruiting |
|
| UC Davis |
|
Eureka Therapeutics |
Hepatocellular Carcinoma |
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) |
Recruiting |
|
| UC Davis |
|
Atara Bio |
Hematologic Malignancies |
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases |
Recruiting |
|
| UCI |
|
Cartesian Therapeutics |
MYASTHENIA GRAVIS (MG) |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Recruiting |
|
| UCSF |
|
Editas Medicine Inc. |
Sickle Cell Disease |
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell D |
Recruiting |
|
| UCSF |
|
Jasper Therapeutics |
Severe Combined Immunodeficiency syndrome |
A Phase 1 study to evaluate the safety and tolerability of tandemly-purified allogeneic CD34+CD90+ HSC administered following conditioning with JSP 191 to achieve engraftment and immune reconstitution in patients with SCID |
Recruiting |
|
| City of Hope & UCLA |
|
City of Hope |
HIV/AIDS |
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients |
No longer active |
|
